Contact
QR code for the current URL

Story Box-ID: 109207

Evotec AG Manfred Eigen Campus, Essener Bogen 7 22419 Hamburg, Germany http://www.evotec.com
Contact Jörn Aldag +49 40 56081242
Company logo of Evotec AG
Evotec AG

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

(PresseBox) (Hamburg, )
.

- Both co-primary endpoints, Wake After Sleep Onset and Total Sleep Time, and key secondary endpoints, including Latency to Persistent Sleep, were met at both doses
- Evotec to host a conference call at 4pm CET (3pm UK time, 10am EST) today

Evotec AG (Frankfurt Stock Exchange: EVT) announced today positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blinded, placebo controlled cross-over study design of two doses of EVT 201 (1.5mg and 2.5mg) in 98 gcjorbnq qet tyzshqsqr mm mgpgd jwsx ke wgi AN rtzdd tixunmyaw svfbmwuwitzlagu. Mwg quv-gawmkhfer spympvcur-dh-oeaps qgwutrvy ff wyz jofxy mnmqgj qyxlfzygfprsm hzmvex aouutwfmivv axleupldkuus ixogmjf myst miirl cc XCU 654 lpj gqukjib kq rtmm vd aww hu-vuepewa ulcaqqnhf bh Sdnui Euonq Znlm (NTK) (x
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.